Computer Image Analysis Reveals C-Myc as a Potential Biomarker for Discriminating between Keratoacanthoma and Cutaneous Squamous Cell Carcinoma

Figure 4

Expression and analysis of β-catenin in Keratoacanthoma (KA) and Cutaneous Squamous Cell Carcinoma (cSCC). (a-1) Immunohistochemical staining. β-Catenin in KA samples was located in cell membranes and in some portions of the cell plasma, and staining in cSCC samples revealed that it was located in cell membranes and in relatively greater portions of cell plasma (20x). (a-2) Tissue area delineation (red: tumor target area; green: mesenchyme; and blue: blank). (a-3) Cytoarchitectonic delineation (green). (a-4) β-catenin DAB Score delineation (Score 0: blue; Score 1+: yellow; Score 2+: orange; and Score 3+: deep red). (b) Percent of Scores 0, 1+, 2+, and 3+ in classes of KA and cSCC samples based on the intensity of β-catenin DAB positivity. β-Catenin Score 2+ (). (c) β-catenin -Scores in KA versus cSCC samples based on intensities of β-catenin DAB positivity (). (d, e) Cross-comparisons of β-catenin Score in the three subtypes of KA (KA-well developed, KA-cSCC, KA-regressing; β-catenin Score 3+ ); β-catenin Score 3+ in KA vs. KA regressing (); KA-cSCC vs. KA regressing ().

(a)

(b)

(c)

(d)

(e)